Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of efinopegdutide in adults with pre-cirrhotic NASH
CTR20233311Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of efinopegdutide in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Merck & Co.. Started Oct 2023; status: completed.
02
Drugs
efinopegdutide
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on CTR20233311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233311.